Moderna announced positive five-year follow-up results from its Phase 2b trial showing its melanoma vaccine candidate (intismeran autogene plus KEYTRUDA) reduced recurrence or death risk by 49% compared to KEYTRUDA alone. The company also expanded its partnership with CEPI to develop a Bundibugyo ebolavirus vaccine, with CEPI committing up to $50 million. Despite the positive news, Moderna's stock fell 2.78% to $45.88.

Plustick Management acquired 499,596 shares of Anterix (ATEX) for approximately $15.81 million in Q1 2026, making it one of the fund's largest holdings. The investment reflects confidence in Anterix's spectrum commercialization business, bolstered by FCC approval to expand 900 MHz broadband allocation from 6 MHz to 10 MHz, a $123 million contracted pipeline, and a prospective $3 billion opportunity pipeline across 60+ potential customers.

Over 15 pharmaceutical companies are actively developing more than 20 pipeline drugs for synovial sarcoma treatment, with promising therapies in various clinical trial stages. Key players including Takara Bio, Immatics, Moderna, Adaptimmune, and Zelluna are advancing innovative approaches such as TCR-T therapies and bispecific antibodies to address the significant unmet medical need in this rare cancer indication.

CytomX Therapeutics announced that management will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company will host fireside chats and one-on-one investor meetings at both events. CytomX is a clinical-stage biopharmaceutical company developing conditionally activated masked PROBODY therapeutics for oncology, with lead candidates including varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

U.S. stock markets rose modestly on May 11, 2026, with tech and AI stocks driving gains despite rising oil prices and inflation concerns. The S&P 500, Nasdaq, and Dow all gained around 0.2%, fueled by semiconductor and AI rallies. However, surging crude oil prices near $99/barrel pressured airlines and rekindled inflation worries, while investment banks predict the Federal Reserve may delay rate cuts until 2026.

U.S. stock futures fell on Monday following President Trump's rejection of Iran's peace proposal response. The S&P 500, Dow, and Nasdaq futures all declined slightly. Key movers included Moderna jumping 8.57% on positive flu-vaccine data, Micron Technologies rising 2.10% after strong weekly gains, and Innodata falling 2.82% despite Friday's surge. Geopolitical tensions and persistent inflation concerns weighed on markets as analysts warn of a divergence between record stock prices and weakening economic fundamentals.

Novavax stock surged 13.16% on Friday, tracking gains in Moderna following the publication of Phase 3 results for Moderna's mRNA-based seasonal flu vaccine in the New England Journal of Medicine. The article also notes Moderna's early-stage hantavirus vaccine research collaboration with the U.S. Army and Korea University. Novavax reported Q1 2025 sales of $139.51 million, beating estimates, though the company posted a net loss of $9 million compared to prior year income.

Moderna's stock rose following positive Phase 1 data for its mRNA hantavirus vaccine, which demonstrated strong immune responses and good tolerability across all dose levels. The results validate Moderna's mRNA platform's versatility for targeting various viral diseases and help offset the company's post-COVID revenue decline. Analysts revised price targets upward based on the trial results, though the stock movement was driven by the data rather than immediate commercial expectations from a recent hantavirus outbreak.

Moderna shares fell 2.05% on Friday despite beating revenue expectations with $389 million (vs. $227.97M consensus) and reporting a narrower adjusted loss of $1.18 per share. The decline was driven by a $2.22 per share litigation settlement charge. The company reiterated 2026 revenue growth guidance of up to 10% and announced progress on its H5 pandemic flu vaccine candidate with a Phase 3 trial launch.

The S&P 500 closed at a record 7,209.01 on Thursday, gaining 1.02% and capping its strongest monthly performance since November 2020 with a 10.4% April gain. Futures point slightly higher for May 1 as markets recover from geopolitical tensions. Strong earnings from major companies and easing concerns are driving bullish sentiment, with Polymarket traders showing 65% confidence in an up opening.

ISCV and IWN are both small-cap value ETFs with distinct trade-offs. ISCV offers a lower expense ratio (0.06% vs 0.24%), higher dividend yield (1.9% vs 1.5%), and is better suited for long-term buy-and-hold investors. IWN has stronger 1-year returns (48.6% vs 37.5%), larger assets under management ($13.4B vs $644.5M), and greater liquidity, making it preferable for active traders despite its higher fees.